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Background: The priorities of research funding bodies govern the research agenda, which has important
implications for the provision of evidence to inform policy. This study examines the research funding landscape for
maternal health interventions in low- and middle-income countries (LMICs).
Methods: This review draws on a database of 2340 academic papers collected through a large-scale systematic
mapping of research on maternal health interventions in LMICs published from 2000–2012. The names of funders
acknowledged on each paper were extracted and categorised into groups. It was noted whether support took a
specific form, such as staff fellowships or drugs. Variations between funder types across regions and topics of
research were assessed.
Results: Funding sources were only reported in 1572 (67%) of articles reviewed. A high number of different funders
(685) were acknowledged, but only a few dominated funding of published research. Bilateral funders, national
research agencies and private foundations were most prominent, while private companies were most commonly
acknowledged for support ‘in kind’. The intervention topics and geographic regions of research funded by the
various funder types had much in common, with HIV being the most common topic and sub-Saharan Africa being
the most common region for all types of funder. Publication outputs rose substantially for several funder types over
the period, with the largest increase among bilateral funders.
Conclusions: A considerable number of organisations provide funding for maternal health research, but a handful
account for most funding acknowledgements. Broadly speaking, these organisations address similar topics and
regions. This suggests little coordination between funding agencies, risking duplication and neglect of some areas
of maternal health research, and limiting the ability of organisations to develop the specialised skills required for
systematically addressing a research topic. Greater transparency in reporting of funding is required, as the role of
funders in the research process is often unclear.
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The role of evidence in policy making and program de-
sign has increased markedly in recent decades, alongside
improvements in tools for collating evidence. Research
funding, in large part, determines the types and amount
of evidence generated, and thus the evidence base for
informed decision-making. Other factors also influence* Correspondence: katharine.footman@lshtm.ac.uk
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unless otherwise stated.what research is done, such as the availability of testable
hypotheses, interventions or technologies; a predilection
for quantifiable and statistically significant results; and
the political importance of a topic. Nevertheless, the pri-
orities of funders oftentimes dictate the research agenda,
and thus govern decisions about what kind of research is
supported, by whom and for what ends [1].
Research funding decisions and the efficiency of such
funding has attracted much critique [2,3]. Imbalances in
health research are well recognised [3,4]. An estimated
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5% of research addresses health problems in these coun-
tries [5]. Funding of health research is well short of global
targets – high income country (HIC) governments spend
under 0.01% of their GDP on Research and Development
(R&D) for health in developing countries; and LMICs well
below 2% of their health budgets on research (averaging
0.18% of GDP in lower-income countries) [3,5].
Clearly, factors such as disease burden and the avail-
ability of cost-effective interventions do not correlate
with the amount of attention given to a health issue,
with some high profile diseases receiving a disproportion-
ately large amount of funding [6,7]. Rather than research
funding agendas being evidence-based and transparent,
support for an issue often depends on how the issue is
understood and portrayed within the global health com-
munity [6]. The comparative advantage of a donor is also
important [8], with, for example, the Bill and Melinda
Gates Foundation initially prioritising research in new
technologies over studies of methods of service delivery
[4], linked to their comparative advantage in technology
and innovation [8].
Examining funding for global health research and the
actors involved in setting research funding priorities is
difficult [9,10]. Development assistance tracking studies
show that development assistance has progressively tar-
geted countries with higher rates of maternal mortality
[11], but these studies often exclude estimates of health
research funding by organisations whose primary pur-
pose is not development, such as national health re-
search agencies, pharmaceutical companies, and some
private foundations, such as the Wellcome Trust [12].
Rigorous assessment of the sources of research fund-
ing and the priorities of different funders will promote
good research governance, and facilitate scrutiny of re-
search funding distribution and donor coordination [2].
This study aims to document the research funding land-
scape in maternal health interventions in LMICs. It uses
the funding acknowledgements of a large database of
peer-reviewed publications to map: the actors acknowl-
edged as funders of maternal health research; the prior-
ity topics and regions they are funding; and changes
occurring between 2000 and 2012.
Methods
The review draws on a database of maternal health
literature developed by the MASCOT/WOTRO project,
which is a large-scale systematic mapping of all maternal
health interventions in LMICs published from 1 January
2000 to 31 August 2012. A systematic mapping of a
broad body of literature on a topic differs from a system-
atic review, which addresses a single, clearly-defined, re-
search question [13]. Systematic maps take into account
all papers published on a topic, and seldom assess thequality of the research being mapped. This approach
was considered appropriate for summarising the funding
of the overall body of maternal health interventional
research.
The MASCOT/WOTRO systematic mapping devel-
oped a sensitive search strategy, using both controlled
vocabulary and free-text terms to identify studies on
Medline (PubMED), which was adapted for subsequent
searches of other electronic sources (Additional file 1).
Seven databases were searched in total (Cumulative Index
to Nursing and Allied Health Literature (CINAHL),
Embase, LILACS, Medline, PopLINE, PsycINFO and Web
of Knowledge).
To be included in the mapping, studies on maternal
health had to address health system or health promotion
interventions, community-based interventions, or single
clinical interventions on four tracer conditions: haemor-
rhage, hypertension, HIV and other STIs, and malaria.
The tracer conditions were selected as they constitute
the two most common causes of direct maternal deaths
(haemorrhage and hypertension), and as HIV and mal-
aria are key causes of indirect maternal deaths in many
settings [14]. We excluded articles on single-clinical inter-
ventions for non-tracer conditions, interventions related
to fertility or infertility, and descriptions of coverage of
routine services. The latter articles were excluded as the
diversity of these studies made it very difficult to standard-
ise data extraction across a large review team. The target
population for interventions had to consist of a maternal
health population (women in pregnancy, childbirth, or
within two years postpartum), or men involved with a
maternal health population (male involvement). General
health system interventions were included provided that
they reported on outcomes in a maternal health popula-
tion. Outcomes could be both quantitative and qualitative,
and all study designs collecting original data were included
if they reported outcome(s) of an intervention. Systematic
reviews were also included, but descriptive studies, narra-
tive reviews, policy discussion papers, academic theses and
books were excluded. Studies were included in the follow-
ing languages: Arabic, English, French, Portuguese and
Spanish.
In total, 45,959 items were added to the online system-
atic review software EPPI-Reviewer 4 (eppi.ioe.ac.uk), of
which 10,881 were duplicate items (Figure 1). The re-
maining records (35,078) were screened independently by
two reviewers for relevance on their title and abstract.
Differences between reviewers were resolved by a third
reviewer. In total, 4507 records were marked for full text
review. For 332 papers, full text documents could not be
located. Of the remaining 4175 papers, 1835 (44.0%) were
excluded after full text review. In total, 32,406 papers were
excluded, mainly as they did not describe an intervention
or outcome (10,577), or were single clinical interventions
Figure 1 Flow chart of overall systematic mapping.
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sion were studies only providing data on utilisation of rou-
tine services (785), published before the year 2000 (6378),
not on maternal health (7906), not in LMICs (704), not
research (1242), and in an excluded language (224). The
final mapping included 2340 papers.
Data extraction was carried out on full text papers in
two stages. First, several variables were extracted from
papers, including the country(ies) of study, country(ies)
of the first author of the paper, study design, interven-
tion topic, outcome data collected and intervention
population. Details of the research funder were also
extracted by directly copying the funding acknowledge-
ments section of each paper or from any other part of
an article where funders were mentioned. To locate in-
formation on funders, data extractors were instructed to
search articles with the following terms: “fund”, “support”,
“financ”, “acknowle”. In a second stage of data extraction,the individual names of every funder on each paper were
extracted and classified into pre-specified categories. At
this stage, it was noted if support was clearly stated to be
‘in kind’, in the form of pharmaceutical supplies, laboratory
support, support for students, or staff fellowships and
salary support. Where funding was said to be provided by
a first organisation through a second organisation (e.g. this
study was funded by funder X through a grant to organisa-
tion Y), only the first organisation (X) was taken to be the
funder of the research. If funding was said to be provided
by an organisation, and the paper also listed donors who
had provided unrestricted support to the organisation, all
listed funders were included.
Data were then transferred into Stata 13 (StataCorp
LP, College Station, TX, USA) and coded. Funders were
grouped into categories to facilitate analysis. We searched
for existing categorisations of research funders, but as no
agreed categorisation of research funders was located, we
Footman et al. Globalization and Health 2014, 10:72 Page 4 of 11
http://www.globalizationandhealth.com/content/10/1/72adapted a classification used in previous studies tracking
official development assistance [12]. These categories were
bilateral, multilateral, global health initiatives, private
foundations, NGOs (international and national), private
sector, and universities or research institutions. Additional
categories for national research agencies (organisations
such as the National Institutes of Health in the United
States), LMIC governments and ‘other’ were noted as
important during the review process and were included as
funder types. Governments of LMICs were classified as bi-
lateral if the funded study took place in another country,
and were classified as national governments if the study
took place in the same country as that of the government.
Internet searches were done to gather information needed
to accurately classify and categorise funders.
Descriptive analysis of the papers was carried out to
assess the number of mentions of each category of
funder, and the type of support specified. The number of
papers funded by each category of funder was tabulated
with the geographic region and intervention topic of
papers. The major funders within each funder type were
also identified, and the topics and countries of the major
funders were then mapped. Analysis was also carried out
to understand how funding patterns have changed over
time.
Results
Who is funding maternal health intervention research?
Of the 2340 papers included in the review after full text
screening, 1572 (67%) included details of their funding
source in the funding acknowledgements. The remaining
768 papers either did not acknowledge their funding
sources, or were unfunded. The number of funders
acknowledged per paper ranged from one to fifteen
(median 2; interquartile range 1–3).Table 1 Type of funding provided, by number of funder men
Funder type No type Staff S
N % N % N
Bilateral 705 97% 15 2% 2
Multilateral 272 98% 2 1% 0
Global Health Initiative 35 95% 0 0% 0
National Research Agencies 652 93% 43 6% 3
Universities 316 88% 32 9% 9
International NGO 150 81% 13 7% 0
National NGO 31 91% 1 3% 0
Private Foundations 372 91% 32 8% 3
Private Sector 145 61% 21 9% 3
National Government 76 97% 1 1% 1
Other 179 80% 36 16% 6
Total 2933 196 2A total of 685 different individual funders were men-
tioned 3266 times in the funding acknowledgements of
the 1572 papers. Of the funders identified, 42% were
acknowledged on more than one paper. The individual
funders were categorised as bilateral (55 funders), multi-
lateral (23), global health initiative (4), national research
agency (47), university or research institute (169), inter-
national NGO (45), national NGO (25), private founda-
tion (65), private sector (71), LMIC governments (40)
and other (141). Funders included in the ‘other’ category
included professional organisations (16), scholarships for
individuals (22), hospitals (31), individuals (3), laborator-
ies (2), regional medical offices (4), religious groups (4),
national health services (2) and other non-profit organi-
sations which could not be categorised as national/inter-
national NGOs or private foundations (20). Additionally,
funders that could not be found on the internet (18) and
funders that could not be classified as fitting into any of
the above categories (19) were placed in the ‘other’
category.
The most common categories of funder were assessed
in terms of how many times they appeared in funding
acknowledgments as a proportion of all funder mentions
(3266). This summed all instances where a funder was
acknowledged, regardless of whether several funders of
the same category were mentioned on the same paper.
By this measure, the most common funders were bilateral
(22% of funder mentions), national research agencies (21%)
and private foundations (12%; Table 1).
What type of funding is being provided?
The majority (90%) of funder mentions were not stated
to be in any specific form, and were taken to be general
financial support (Table 1). A tenth of funding mentions
were for support in the form of drugs, laboratory support,tions
tudent Drugs Laboratory Total
% N % N % N %
0% 4 1% 1 0% 727 22%
0% 0 0% 3 1% 277 8%
0% 1 3% 1 3% 37 1%
0% 1 0% 0 0% 699 21%
3% 1 0% 1 0% 359 11%
0% 19 10% 3 2% 185 6%
0% 1 3% 1 3% 34 1%
1% 1 0% 0 0% 408 12%
1% 57 24% 12 5% 238 7%
1% 0 0% 0 0% 78 2%
3% 1 0% 2 1% 224 7%
7 86 24 3266 100%
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for students. Support in the form of staff funding was the
most common type of support ‘in kind’ (6% of funder
mentions), followed by donation of drugs (3%). While gen-
eral financial support comprised more than 90% of fund-
ing for most funders, 39% of private sector funding was
for support in kind, predominantly in the form of drugs
(24%), staff funding (9%) or laboratory support (5%). Sup-
port in the form of staff funding was also more prominent
among funders in the ‘other’ category (16%), followed by
universities (9%) research agencies (8%) and international
NGOs (7%).
Which funders are dominating maternal health research
funding?
Figure 2 shows the number of mentions of each funder
type that are attributed to the three largest funders inFigure 2 Number of funder mentions attributed to the three largest f
International Development; CDC Centers for Disease Control; WHO World H
Emergency Plan For AIDS Relief; ANRS Agence Nationale de Recherche sur
Pediatric AIDS Foundation; Gates Bill & Melinda Gates Foundation; Wellcom
major funders: Roll Back Malaria, Global Fund (Global health initiatives); L'Ins
Copenhagen, University of North Carolina (Universities); Population Council
ICDDR,B, Childbirth Connection (National NGOs); MacArthur Foundation (Pr
Africa, Government of Brazil (National Governments).each category. Several categories of funder, such as multi-
lateral, bilateral, private foundations and national research
agencies, were dominated by their three largest funders,
with numerous other funders in each category making up
a low proportion of funder mentions (3%-35%). The lar-
gest funders in other categories, such as the private sector,
NGOs and universities, did not dominate their sectors,
with funders other than the top three making up the high-
est proportion of overall funder mentions (53% to 89%).
As individual funders, the National Institute of Health
(NIH) (12%), the US Agency for International
Development (USAID) (8%) and the Bill and Melinda
Gates Foundation (BMGF) (6%) made up the highest
proportions of funder mentions. These funders together
were acknowledged on 40% of all papers with a funder
acknowledgement (and 22% of all papers, including those
with no funder acknowledged). Other individual fundersunders in each funder type. Abbreviations: DFID UK Department of
ealth Organisation; EU European Union; PEPFAR US President’s
le Sida; MRC Medical Research Council; EGPAF Elizabeth Glaser
e Trust; BI Boehringer Ingelheim; GSK GlaxosmithKline. Unlabelled
titut de recherche pour le développement (IRD), University of
, Medecins sans Frontieres (International NGOs); Health Foundation,
ivate Foundations); Government of Thailand, Government of South
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Department for International Development (DFID), the
US Centers for Disease Control (CDC), the European
Union (EU) and the World Health Organization (WHO).
Where are funders focussing their research?
Figure 3 shows the funders that were most frequently
acknowledged in each geographic region (including only
studies with a funder acknowledged). Bilateral bodies
were the most commonly acknowledged funder in every
geographic region, ranging from 19% of papers on Latin
America to 37% of papers on the Middle East/North
Africa. National research agencies commonly funded
papers in Latin America where they were acknowledged
on 27% of papers, and they also made up 20% of multi-
county studies and studies in sub-Saharan Africa. Private
foundations played more of a role in the Middle East/
North Africa region, where they funded 24% of papers.
Figure 4 shows the regions where each funder type
most commonly funded research. For every funder, the
most common geographic region funded was sub-
Saharan Africa (43%-84% of their papers). Global Health
Initiatives, in particular, have focused on sub-Saharan
Africa (84% of the papers they funded). The second most
common region for most funder types was East Asia/
Pacific (0% to 12%), suggesting a limited geographical
diversity across funder types.
What types of intervention topics are being funded?
Figure 5a shows the funders that were most frequently
acknowledged by papers on each intervention topic. The
two main causes of maternal mortality – haemorrhage
and hypertension – had a high proportion of papers
without any funder (37% and 46% respectively). Studies
on STIs other than HIV were also often without ac-
knowledged external funding. National research agencies
and private foundations seemed to play a greater role
funding papers on HIV and STIs, while papers onFigure 3 The distribution of funder types by major regions.malaria in pregnancy were not dominated by any par-
ticular funder type. Bilateral agencies played the greatest
role in funding papers on health systems (24%), promo-
tion (25%) and financing (35%).
Figure 5b shows the five largest funders acknowledged
for each topic of maternal health. For topics such as
HIV, there is clearly one dominant funder (NIH), whereas
other topics such as emergency obstetric care, haemor-
rhage and health promotion have two or three dominant
funders (USAID, Gates Foundation, DfID). Topics such as
non-HIV STIs and hypertension are not clearly dominated
by any one funder. This lack of a dominant funder may
suggest that there is a broader range of funders with an
interest in these topics. However, Figure 6 suggests that it
might instead reflect the fact that there are no funder
types prioritising these topics. Figure 6 shows the inter-
vention topics that each funder type most commonly
funded. For every funder type, the main focus was HIV
(ranging from 25% to 70% of papers) and health systems
interventions (ranging from 15% to 63% of papers). Topics
such as haemorrhage, hypertension and STIs did not seem
to be prioritised by any category of funder, ranging from 0
to 13% of each funder’s papers.
How has funding changed over time?
Finally, we examined variations in the number of papers
acknowledging each type of funder over the time period
2000 to 2011. Though the publication output for each
funder type rose over time, different rates of increase
were noted, and outputs plateaued for some funders
(Figure 7). The rate of increase in outputs slowed mark-
edly or flattened for bilateral, private sector, university
and national research councils after 2006. Funding by
private foundations rose rapidly after 2004, while multi-
lateral funding increased at a relatively constant rate.
The number of papers acknowledging national NGOs,
local governments and global health initiatives remained
fairly low throughout the time period.
Figure 4 Regions addressed by different funder types (as a % of all papers).
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Almost 700 funders were located in this systematic map-
ping of maternal health intervention research. A small
fraction of these funders dominate published research,
supporting assertions that relatively few donors identify
maternal health as a key focus area [15]. Most promin-
ent in our review are bilateral funders and national re-
search agencies, while private foundations also support a
sizable proportion of research outputs. Few studies were
funded by national governments or NGOs suggesting
that although funding of research by the public sector in
LMICs has risen over time [14,16], it remains suboptimal.
Though tracking research funding amounts and out-
puts is difficult [17], funding allocations for maternal
health research are disproportionate to the burden of
disease [18,19]. There were about half a million publica-
tions on health in LMICs between 2002 and 2011 [17],
which dwarfs the 35,078 publications we located on
maternal health in a similar period (before applying
exclusion criteria). These inequities in funding were also
noted in the field of neglected disease, which received
only about 1% of all Research and Development (R&D)
investments in 2010 [17]. Funding for HIV research
dominates other maternal health conditions, as occurs
in neglected diseases (about 70% of R&D is on HIV, mal-
aria and tuberculosis) [20]. Importantly the two main
causes of maternal mortality – haemorrhage and hyper-
tension – had a high proportion of papers without any
funder, suggesting there has been inadequate support for
these key areas of research.Private sector funding of drug and laboratory support
is several fold more common than in other funder cat-
egories. The plateau noted in industry funding of mater-
nal research in recent years has occurred in all health
topics, though this is the most difficult funding source
to track [21]. Under-funding of pharmaceutical R&D for
maternal health is a symptom of a market failure. While
specific global initiatives have successfully overcome
market failures in malaria, for example, there have been
no similar global initiatives for maternal health. Globally,
maternal health R&D is comparable to that for single
conditions in high-income settings (for example, fewer
maternal health drugs are in the pipeline than for
Crohn’s disease) [18]. Boosting R&D for maternal health
will require incentives for pharmaceutical investment
and measures to convince governments, philanthropic
agencies and other donors of what could be achieved.
Strengthening R&D is an important complementary
strategy to health service provision for addressing the
global burden of maternal diseases [18,19]. The WHO
Commission on Macroeconomics and Health identified
maternal and perinatal health as second only to infec-
tious disease as a priority for global health research [22].
In spite of the research councils of both India and South
Africa identifying maternal and perinatal health as prior-
ities, overall R&D investment by both governments is
small, ($55.2 M and $175.8 M, respectively) [19]. India,
in particular, allocated <5% of its grants in reproductive
health and nutrition to maternal or perinatal health [19].
Clearly, the high level of priority accorded to maternal
Figure 5 The distribution of funder types by topic. a. A stacked percentage bar chart showing the distribution of funder types for each topic.
b. Five largest funders for each material health topic.
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documents has not translated into actual funding.
The study identified commonalities across funder
types in the intervention topics and geographic regions
covered, with HIV the topic most commonly addressed
by each category of donor, and the majority of studies
for all funders being set in sub-Saharan Africa. This
echoes previous resource-tracking studies [12], and geo-
graphical gaps identified in research, such as in Latin
America and the Middle East [15]. Having all key players
addressing similar topics and geographical areas likely
duplicates efforts and diffuses focus among funders and
researchers. It also surely signals the absence of a long-
term, carefully planned, progressive accumulation of
knowledge on a topic, built upon specialised skills in thearea. Having only a few major funders limits diversity of
funding [23], such that, if a condition is accorded low
priority by these funders, such as STIs other than HIV,
there are few alternative funding sources, and little
research is done in that area. An alternative approach is
worth considering: the key funders each take responsibility
for research on certain topics and regions, and develop
specialised expertise both within their organisation and in
researchers. Coordination of health research and develop-
ment at a global level is a long-standing objective, with
many initiatives in this area [17,24,25]. Coordination would,
however, necessitate sharing of information between fun-
ders, and joint priority setting, planning and action [24].
The methods employed in this research have been
used to complement other ways of tracking research
Topic No funder Bilateral Multilateral
Global 
Health 
Initiative
National 
Research 
Agency
Private 
Foundation Universities
National 
NGO
National 
Government
Private 
Sector
International 
NGO Other
N % N % N % N % N % N % N % N % N % N % N % N %
Haemorrhage 95 12 38 6 13 5 0 0 15 3 36 10 21 8 2 6 1 1 8 5 17 10 14 7
Hypertension 136 18 22 4 14 6 0 0 26 5 17 5 37 13 4 11 5 7 10 6 3 2 20 11
HIV 205 27 187 31 62 26 26 70 303 58 94 25 97 35 9 26 31 40 106 62 91 52 62 33
STIs 42 6 19 3 14 6 0 0 27 5 25 7 9 3 1 3 3 4 7 4 4 2 7 4
Malaria 71 9 82 14 39 16 10 27 45 9 83 22 51 18 2 6 6 8 29 17 16 9 29 15
Health Systems 245 32 304 51 124 51 18 49 146 28 163 44 81 29 22 63 33 43 26 15 58 33 61 32
Emergency Obstetric Care 66 9 71 12 27 11 0 0 23 4 47 13 19 7 6 17 7 9 6 4 12 7 13 7
Demand-side Financing 12 2 37 6 11 5 5 14 12 2 13 4 2 1 0 0 7 9 1 1 4 2 2 1
Health Promotion 92 12 153 25 49 20 0 0 40 8 73 20 23 8 3 9 12 16 11 6 29 17 34 18
Birth Preparedness 32 4 58 10 14 6 0 0 10 2 23 6 4 1 2 6 4 5 3 2 3 2 9 5
TBAs 29 4 39 7 14 6 0 0 14 3 34 9 9 3 1 3 3 4 4 2 11 6 8 4
Male Involvement 15 2 28 5 12 5 0 0 12 2 6 2 5 2 0 0 2 3 4 2 11 6 9 5
Transport 9 1 23 4 7 3 0 0 4 1 7 2 3 1 0 0 3 4 0 0 2 1 2 1
Maternity Waiting Homes 7 1 5 1 2 1 0 0 0 0 3 1 2 1 0 0 0 0 0 0 2 1 6 3
Study Design
Randomised Trials 63 8 77 13 48 20 0 0 105 20 70 19 52 19 6 17 10 13 60 35 26 15 37 20
Systematic Reviews 94 12 36 6 27 11 0 0 36 7 35 10 62 22 5 14 3 4 10 6 3 2 39 21
TOTAL 768 602 242 37 527 370 281 35 77 172 174 190
<6 6-28 >28
Figure 6 Topics addressed by different funder types (as a % of total papers not funder mentions).
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number of limitations. Funding acknowledgements of
published papers likely incur reporting biases, for example,
by overestimating funders that have publication output
requirements in their funding. Additionally, limiting the
mapping to certain health system interventions and tracer
conditions, may underestimate the role of funders thatFigure 7 Changes in the number of papers acknowledging each fundprioritise other conditions, or formative research such as
needs assessments or descriptive cross-sectional studies.
Similarly, we were only able to count the number of pa-
pers acknowledging a funder, not the amount of funding
provided, or the impact of the research. As the unit of ana-
lysis was publications, not studies, multiple papers from
one study were double counted. Vague language, such aser type between 2000–2011.
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may misclassify funders that provided organisational or
management support, rather than financial support. Fi-
nally, we only have information on the stated funder, not
the source of the funders’ resources. Agencies’ funding is
complex and interlinked, and the funding bodies ac-
knowledged may have received funding from another
donor [12,26].
This study is therefore not intended to compare the
various roles of funding bodies and their financial con-
tributions, but to facilitate scrutiny of research govern-
ance by mapping out the various actors at play, and the
research that they fund. Certain categories of funder
were the most dominant in our analysis - bilateral do-
nors, national research agencies and private foundations.
It is not possible to say whether these types of funder
are more or less likely to promote an evidence-informed
research agenda, as this will largely depend on the indi-
vidual organisation. Certain types of funder have more
commonly come under criticism, such as private sector
funders for their potential vested interests influencing
study outcomes [27,28], and private foundations for their
potential lack of accountability, links to private parent
corporations and their setting of funding priorities
according to personal interests [15,23,29,30]. However,
regardless of category, every funder has its own agenda
and may face its own perverse incentives. It is the govern-
ance of funders and the mechanisms in place to promote
informed funding decisions that will decide their ability to
consider evidence when setting research agendas.
Aside from their role in setting the agenda for research,
funders also have the potential to influence the research
process of the studies that they fund. This study found
there was insufficient information to summarise the role
of funders in most studies, one of the STROBE reporting
recommendations [31]. Standardising reporting of the
types of funding provided would promote transparency
about funders’ contributions and a better understanding
of their roles. Tracking the ways in which funding
agendas are set (the extent to which evidence influences
these decisions) and the presence of inter-funder coordin-
ation, might also promote accountability in research
governance. Efficiency of funders’ resource use could be
examined, by contrasting the scale of funding provided by
different actors with the outputs mapped by our study.
Conclusion
In conclusion, there is considerable diversity in the funding
sources acknowledged by maternal health intervention
research, though only a handful account for most publica-
tion outputs. Bilateral funders, national research agencies
and private foundations were most often acknowledged,
while the private sector commonly provides support ‘in
kind’, often taking the form of pharmaceuticals. Despite thediversity of funding sources, there appears to be much
similarity between the priority regions and topics of the
major funders, suggesting that coordination between fun-
ders is poor.
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